🔗 Share this article

As the United States continues making historic adjustments to its immunization recommendations, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccinations during the global health crisis and has concentrated on alleged deaths after Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Program

Agency leaders were set to reveal sweeping revisions to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would put the US out of step with many the global community with no evidence for benefit. This reveal has been pushed back until the next year.

Instead of the director of the vaccine center, Dr. Høeg is listed to speak at the meeting. She was recently named acting director of the FDA’s CDER, the fifth individual to head the center this calendar year.

A Shift at the FDA

The acting appointment may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad solidify control at the agency – and it points to a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US in order to be more like Denmark's approach, a society with universal health coverage and a population approximately the population of Wisconsin’s.

To date comments, she has kept her attention on vaccination policy – usually the domain of Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in medication creation, oversight or management, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in leading a large organization. She is not an expert in industry regulation.”

Previous heads of CBER would “understand regulatory frameworks and the underlying principles of medication creation”, noted Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who led the center have had.”

This division has an immense range of responsibilities at the agency, Woodcock pointed out.

“The public just focuses on the new drug program, but the generic program clears a multitude of generic drugs. There is also a biosimilars program, non-prescription drug unit and so forth, and every single one must be supervised,” she explained. “The area you overlook, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant leadership element to the role, which oversees in excess of 5,000 staff members. “It’s a enormous leadership role, if you execute it properly,” she concluded.

Official Statement and Controversial Policies

In response to concerns about Dr. Høeg's fitness for the role and whether this assignment represents greater collaboration among FDA leaders on immunizations, a press secretary responded that the “inquiries are based on inaccurate presumptions”.

“Her resume aligns with the functions of her position,” the official said, citing the time Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a disputed one-day therapy clearance system that reportedly concerned her predecessors. “How are these drugs being selected for this voucher program? Who is making the decisions?” Dr. Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

In general, he said, “the agency appears to be shifting towards less stringent regulations of pharmaceuticals, except for vaccines.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, track record, some experts have noted. She authored a analysis using unverified crowd-sourced reports to estimate the rate of myocarditis following COVID-19 vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the new administration included altering guidelines for novel immunizations and halting “non-essential” vaccines, she said following the vote on a audio program. At the agency, Høeg has according to sources proposed preventing adolescent males from obtaining Covid vaccines.

“She is an all-around dogmatist who commences with her conclusions and tailors the evidence to retrofit the data in a very disingenuous, fraudulent manner,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow contrarians, {like|